RecruitingPhase 2NCT05851391

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)

Sponsor

University of California, San Francisco

Enrollment

30 participants

Start Date

Aug 7, 2023

Study Type

INTERVENTIONAL

Conditions

Seizures Status Epilepticus Hypoxia-Ischemia, Brain Refractory Status Epilepticus Heart Arrest Anoxic-Ischemic Encephalopathy Anoxia-Ischemia, Cerebral

Summary

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Burst Suppression EEG Target Intravenous Anesthesia and a drug called Seizure Suppression EEG Target Intravenous Anesthesia for people with anoxia-ischemia, cerebral, anoxic-ischemic encephalopathy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBurst Suppression EEG Target Intravenous Anesthesia

The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.

DRUGSeizure Suppression EEG Target Intravenous Anesthesia

is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.